PARP1 expression drives the synergistic antitumor activity of trabectedin and PARP1 inhibitors in sarcoma preclinical models

[1]  Robin L. Jones,et al.  Efficacy and Safety of Trabectedin or Dacarbazine for Metastatic Liposarcoma or Leiomyosarcoma After Failure of Conventional Chemotherapy: Results of a Phase III Randomized Multicenter Clinical Trial. , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[2]  F. Hamdy,et al.  DNA-PKcs and PARP1 Bind to Unresected Stalled DNA Replication Forks Where They Recruit XRCC1 to Mediate Repair. , 2016, Cancer research.

[3]  E. Sausville,et al.  Phase I Safety, Pharmacokinetic, and Pharmacodynamic Study of the Poly(ADP-ribose) Polymerase (PARP) Inhibitor Veliparib (ABT-888) in Combination with Irinotecan in Patients with Advanced Solid Tumors , 2016, Clinical Cancer Research.

[4]  H. Linden,et al.  Phase I Study of Veliparib (ABT-888) Combined with Cisplatin and Vinorelbine in Advanced Triple-Negative Breast Cancer and/or BRCA Mutation–Associated Breast Cancer , 2016, Clinical Cancer Research.

[5]  C. Galmarini,et al.  Unique features of trabectedin mechanism of action , 2016, Cancer Chemotherapy and Pharmacology.

[6]  C. Galmarini,et al.  Synergistic Effect of Trabectedin and Olaparib Combination Regimen in Breast Cancer Cell Lines , 2015, Journal of breast cancer.

[7]  G. Shapiro,et al.  Homologous Recombination Deficiency: Exploiting the Fundamental Vulnerability of Ovarian Cancer. , 2015, Cancer discovery.

[8]  Wei Yuan,et al.  DNA-Repair Defects and Olaparib in Metastatic Prostate Cancer. , 2015, The New England journal of medicine.

[9]  M. Stratton,et al.  Combinations of PARP Inhibitors with Temozolomide Drive PARP1 Trapping and Apoptosis in Ewing’s Sarcoma , 2015, PloS one.

[10]  F. Engert,et al.  PARP Inhibitors Sensitize Ewing Sarcoma Cells to Temozolomide-Induced Apoptosis via the Mitochondrial Pathway , 2015, Molecular Cancer Therapeutics.

[11]  B. Ueberheide,et al.  TIMELESS Forms a Complex with PARP1 Distinct from Its Complex with TIPIN and Plays a Role in the DNA Damage Response , 2015, Cell reports.

[12]  T. Helleday,et al.  Timeless Interacts with PARP-1 to Promote Homologous Recombination Repair. , 2015, Molecular cell.

[13]  M. O’Connor,et al.  Extent of radiosensitization by the PARP inhibitor olaparib depends on its dose, the radiation dose and the integrity of the homologous recombination pathway of tumor cells. , 2015, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[14]  J. Mora,et al.  Correction: The PARP inhibitor olaparib enhances the sensitivity of Ewing sarcoma to trabectedin , 2017, OncoTarget.

[15]  C. Scott,et al.  Poly (ADP-ribose) polymerase inhibitors: recent advances and future development. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[16]  J. Bendell,et al.  Phase I study of olaparib plus gemcitabine in patients with advanced solid tumours and comparison with gemcitabine alone in patients with locally advanced/metastatic pancreatic cancer. , 2015, Annals of oncology : official journal of the European Society for Medical Oncology.

[17]  J. Blay,et al.  Interruption versus continuation of trabectedin in patients with soft-tissue sarcoma (T-DIS): a randomised phase 2 trial. , 2015, The Lancet. Oncology.

[18]  Ayala Hubert,et al.  Olaparib monotherapy in patients with advanced cancer and a germline BRCA1/2 mutation. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[19]  A. Jeyasekharan,et al.  NF-κB signaling mediates acquired resistance after PARP inhibition , 2015, Oncotarget.

[20]  I. Ellis,et al.  Biological and clinical significance of PARP1 protein expression in breast cancer , 2014, Breast Cancer Research and Treatment.

[21]  D. Matei,et al.  Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: A preplanned retrospective analysis of outcomes by BRCA status in a randomised phase 2 trial , 2014 .

[22]  E. Kohn,et al.  Combination cediranib and olaparib versus olaparib alone for women with recurrent platinum-sensitive ovarian cancer: a randomised phase 2 study. , 2014, The Lancet. Oncology.

[23]  Lori Minasian,et al.  Phase I/Ib study of olaparib and carboplatin in BRCA1 or BRCA2 mutation-associated breast or ovarian cancer with biomarker analyses. , 2014, Journal of the National Cancer Institute.

[24]  James H. Doroshow,et al.  Rationale for Poly(ADP-ribose) Polymerase (PARP) Inhibitors in Combination Therapy with Camptothecins or Temozolomide Based on PARP Trapping versus Catalytic Inhibition , 2014, The Journal of Pharmacology and Experimental Therapeutics.

[25]  V. Giranda,et al.  Targeting DNA repair with combination veliparib (ABT-888) and temozolomide in patients with metastatic castration-resistant prostate cancer , 2014, Investigational New Drugs.

[26]  J. Blay,et al.  Randomised phase III trial of trabectedin versus doxorubicin-based chemotherapy as first-line therapy in translocation-related sarcomas. , 2014, European journal of cancer.

[27]  Alan Ashworth,et al.  Genome-wide profiling of genetic synthetic lethality identifies CDK12 as a novel determinant of PARP1/2 inhibitor sensitivity. , 2014, Cancer research.

[28]  Y. Pommier,et al.  Stereospecific PARP Trapping by BMN 673 and Comparison with Olaparib and Rucaparib , 2013, Molecular Cancer Therapeutics.

[29]  Y. Pommier,et al.  Dual Targeting of EWS-FLI1 Activity and the Associated DNA Damage Response with Trabectedin and SN38 Synergistically Inhibits Ewing Sarcoma Cell Growth , 2013, Clinical Cancer Research.

[30]  T. Helleday.  Putting poly (ADP-ribose) polymerase and other DNA repair inhibitors into clinical practice , 2013, Current opinion in oncology.

[31]  Ying Feng,et al.  Proteomic Markers of DNA Repair and PI3K Pathway Activation Predict Response to the PARP Inhibitor BMN 673 in Small Cell Lung Cancer , 2013, Clinical Cancer Research.

[32]  Do Joong Park,et al.  Combining PARP-1 Inhibition and Radiation in Ewing Sarcoma Results in Lethal DNA Damage , 2013, Molecular Cancer Therapeutics.

[33]  A. Ashworth,et al.  A Genetic Screen Using the PiggyBac Transposon in Haploid Cells Identifies Parp1 as a Mediator of Olaparib Toxicity , 2013, PloS one.

[34]  K. O'Byrne,et al.  Targeting Nuclear Factor-Kappa B to Overcome Resistance to Chemotherapy , 2013, Front. Oncol..

[35]  N. Curtin,et al.  A phase II study of the potent PARP inhibitor, Rucaparib (PF-01367338, AG014699), with temozolomide in patients with metastatic melanoma demonstrating evidence of chemopotentiation , 2013, Cancer Chemotherapy and Pharmacology.

[36]  Nicola J. Curtin,et al.  DNA repair dysregulation from cancer driver to therapeutic target , 2012, Nature Reviews Cancer.

[37]  Y. Pommier,et al.  Trapping of PARP1 and PARP2 by Clinical PARP Inhibitors. , 2012, Cancer research.

[38]  Michael Peyton,et al.  Proteomic profiling identifies dysregulated pathways in small cell lung cancer and novel therapeutic targets including PARP1. , 2012, Cancer discovery.

[39]  Arul M Chinnaiyan,et al.  PARP-1 inhibition as a targeted strategy to treat Ewing's sarcoma. , 2012, Cancer research.

[40]  S. Ramaswamy,et al.  Systematic identification of genomic markers of drug sensitivity in cancer cells , 2012, Nature.

[41]  G. Giaccone,et al.  A Phase I Combination Study of Olaparib with Cisplatin and Gemcitabine in Adults with Solid Tumors , 2012, Clinical Cancer Research.

[42]  Larry Rubinstein,et al.  A Phase I Study of Veliparib in Combination with Metronomic Cyclophosphamide in Adults with Refractory Solid Tumors and Lymphomas , 2012, Clinical Cancer Research.

[43]  A. Ashworth,et al.  The DNA damage response and cancer therapy , 2012, Nature.

[44]  J. Thigpen.  Olaparib Maintenance Therapy in Platinum-Sensitive Relapsed Ovarian Cancer , 2012 .

[45]  Y. Pommier,et al.  Phase I study of PARP inhibitor ABT-888 in combination with topotecan in adults with refractory solid tumors and lymphomas. , 2011, Cancer research.

[46]  J. Blay,et al.  ERCC5/XPG, ERCC1, and BRCA1 gene status and clinical benefit of trabectedin in patients with soft tissue sarcoma , 2011, Cancer.

[47]  Kazuhiro Takahashi,et al.  The Activity of Trabectedin As a Single Agent or in Combination with Everolimus for Clear Cell Carcinoma of the Ovary , 2011, Clinical Cancer Research.

[48]  J. Blay,et al.  Predictive impact of DNA repair functionality on clinical outcome of advanced sarcoma patients treated with trabectedin: a retrospective multicentric study. , 2011, European journal of cancer.

[49]  A. Ashworth,et al.  Synthetic lethality of PARP inhibition in cancers lacking BRCA1 and BRCA2 mutations , 2011, Cell cycle.

[50]  S. Gruber,et al.  MRE11 deficiency increases sensitivity to poly(ADP-ribose) polymerase inhibition in microsatellite unstable colorectal cancers. , 2011, Cancer research.

[51]  J. Larkin,et al.  A phase I study of the safety and tolerability of olaparib (AZD2281, KU0059436) and dacarbazine in patients with advanced solid tumours , 2011, British Journal of Cancer.

[52]  J. Khan,et al.  Ecteinascidin 743 interferes with the activity of EWS-FLI1 in Ewing sarcoma cells. , 2011, Neoplasia.

[53]  Ricky A. Sharma,et al.  Molecular and Cellular Pathobiology Cancer Research Poly ( ADP-Ribose ) Polymerase Is Hyperactivated in Homologous Recombination – Defective Cells , 2010 .

[54]  Jan Lubinski,et al.  Poly(ADP)-ribose polymerase inhibition: frequent durable responses in BRCA carrier ovarian cancer correlating with platinum-free interval. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[55]  S. Kaufmann,et al.  PARP inhibition: PARP1 and beyond , 2010, Nature Reviews Cancer.

[56]  P. Allavena,et al.  Antitumor and anti-inflammatory effects of trabectedin on human myxoid liposarcoma cells. , 2010, Cancer research.

[57]  P. Glazer,et al.  Inhibition of poly(ADP-ribose) polymerase down-regulates BRCA1 and RAD51 in a pathway mediated by E2F4 and p130 , 2010, Proceedings of the National Academy of Sciences.

[58]  A. Ashworth,et al.  Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers. , 2009, The New England journal of medicine.

[59]  Claus Scheidereit,et al.  A nuclear poly(ADP-ribose)-dependent signalosome confers DNA damage-induced IkappaB kinase activation. , 2009, Molecular cell.

[60]  Eric F. Johnson,et al.  Acquired Resistance to Combination Treatment with Temozolomide and ABT-888 Is Mediated by Both Base Excision Repair and Homologous Recombination DNA Repair Pathways , 2009, Molecular Cancer Research.

[61]  A. Harris,et al.  Phase I Study of the Poly(ADP-Ribose) Polymerase Inhibitor, AG014699, in Combination with Temozolomide in Patients with Advanced Solid Tumors , 2008, Clinical Cancer Research.

[62]  R. Freimanis,et al.  Polygenic model of DNA repair genetic polymorphisms in human breast cancer risk. , 2008, Carcinogenesis.

[63]  A. Lau,et al.  4-[3-(4-cyclopropanecarbonylpiperazine-1-carbonyl)-4-fluorobenzyl]-2H-phthalazin-1-one: a novel bioavailable inhibitor of poly(ADP-ribose) polymerase-1. , 2008, Journal of medicinal chemistry.

[64]  J. Cigudosa,et al.  Extreme sensitivity to Yondelis® (Trabectedin, ET‐743) in low passaged sarcoma cell lines correlates with mutated p53 , 2007, Journal of cellular biochemistry.

[65]  Thomas Helleday,et al.  Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase , 2007, Nature.

[66]  Alan Ashworth,et al.  Deficiency in the repair of DNA damage by homologous recombination and sensitivity to poly(ADP-ribose) polymerase inhibition. , 2006, Cancer research.

[67]  Pablo Tamayo,et al.  Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[68]  Alan Ashworth,et al.  Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy , 2005, Nature.

[69]  K. Lohman,et al.  The ADPRT V762A Genetic Variant Contributes to Prostate Cancer Susceptibility and Deficient Enzyme Function , 2004, Cancer Research.

[70]  C. Simbulan-Rosenthal,et al.  PARP-1 binds E2F-1 independently of its DNA binding and catalytic domains, and acts as a novel coactivator of E2F-1-mediated transcription during re-entry of quiescent cells into S phase , 2003, Oncogene.

[71]  M. Macleod,et al.  Regulation of BRCA1 Expression by the Rb-E2F Pathway* , 2000, The Journal of Biological Chemistry.

[72]  Masahiko S. Satoh,et al.  Role of poly(ADP-ribose) formation in DNA repair , 1992, Nature.

[73]  B I Sikic,et al.  Multidrug (pleiotropic) resistance in doxorubicin-selected variants of the human sarcoma cell line MES-SA. , 1985, Cancer research.